Literature DB >> 11529909

Effects of granulocyte-macrophage colony stimulating factor (GM-CSF) in vivo on cytokine production and proliferation by spleen cells.

S Khatami1, E Brummer, D A Stevens.   

Abstract

GM-CSF is a potent stimulator of haematopoietic cells as well as some functions of granulocytes and macrophages. GM-CSF has many clinical uses; however, little is known about the effects of GM-CSF treatment in vivo on the responses of tissue lymphocytes in terms of secretion of Th-1 and Th-2 cytokines. We investigated this issue by measuring the responses of spleen cells from mice 24 h after treatment i.p. with saline or rmGM-CSF. GM-CSF at 16.7-50.0 microg/kg significantly increased (P < 0.01) spleen cellularity 2-2.5-fold and enhanced proliferative responses of non-stimulated (no mitogen) as well as concanavalin A (Con A)-stimulated spleen cells. Secretion of IFN-gamma by Con A (2.5 microg/ml)-stimulated spleen cells was significantly (P < 0.01) increased from 1.8 microg/ml by control spleen cells to 5.2 microg/ml by GM-CSF spleen cells. IL-10 production was greater (0.25 microg/ml, P < 0.05) by Con A-stimulated spleen cells from GM-CSF-treated mice compared to control spleen cells (0.06 microg/ml). By contrast, there were no significant differences in IL-4 production by Con A-stimulated spleen cells from the different groups. These results show that GM-CSF treatment increases spleen cellularity and primes lymphocytes for enhanced responses. The enhanced production of Th-1 cytokines by primed lymphocytes may partially explain the beneficial role of in vivo administration of GM-CSF in several clinical situations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529909      PMCID: PMC1906115          DOI: 10.1046/j.1365-2249.2001.01600.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

Review 1.  Granulocyte-macrophage colony-stimulating factor: more than a hemopoietin.

Authors:  R L Monroy; T A Davis; T J MacVittie
Journal:  Clin Immunol Immunopathol       Date:  1990-03

Review 2.  G- and GM-CSF.

Authors:  M Middleton; N Thatcher
Journal:  Int J Antimicrob Agents       Date:  1998-05       Impact factor: 5.283

3.  Granulocyte-macrophage and macrophage colony-stimulating factors activate intramacrophage killing of Leishmania mexicana amazonensis.

Authors:  J L Ho; S G Reed; E A Wick; M Giordano
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

Review 4.  Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness.

Authors:  C Ruef; D L Coleman
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

5.  Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils.

Authors:  J C Gasson; R H Weisbart; S E Kaufman; S C Clark; R M Hewick; G G Wong; D W Golde
Journal:  Science       Date:  1984-12-14       Impact factor: 47.728

6.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.

Authors:  K S Antman; J D Griffin; A Elias; M A Socinski; L Ryan; S A Cannistra; D Oette; M Whitley; E Frei; L E Schnipper
Journal:  N Engl J Med       Date:  1988-09-08       Impact factor: 91.245

7.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  S J Brandt; W P Peters; S K Atwater; J Kurtzberg; M J Borowitz; R B Jones; E J Shpall; R C Bast; C J Gilbert; D H Oette
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

8.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

9.  Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor.

Authors:  R E Champlin; S D Nimer; P Ireland; D H Oette; D W Golde
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

10.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  4 in total

1.  Atrial fibrillation is associated with hematopoietic tissue activation and arterial inflammation.

Authors:  Philip Joseph; Amorina Ishai; Megan MacNabb; Amr Abdelbaky; Zachary R Lavender; Jeremy Ruskin; Matthias Nahrendorf; Ahmed Tawakol
Journal:  Int J Cardiovasc Imaging       Date:  2015-09-28       Impact factor: 2.357

2.  Protective effects of adenosine A2A receptor agonist in ventilator-induced lung injury in rats.

Authors:  Chin-Ming Chen; Oscar Penuelas; Kieran Quinn; Kuo-Chen Cheng; Chien-Feng Li; Haibo Zhang; Arthur S Slutsky
Journal:  Crit Care Med       Date:  2009-07       Impact factor: 7.598

3.  Effect of Mucosal Cytokine Administration on Selective Expansion of Vaginal Dendritic Cells to Support Nanoparticle Transport.

Authors:  Renuka Ramanathan; Jaehyung Park; Sean M Hughes; William R Lykins; Hunter R Bennett; Florian Hladik; Kim A Woodrow
Journal:  Am J Reprod Immunol       Date:  2015-06-27       Impact factor: 3.777

4.  Oxaliplatin Treatment Alters Systemic Immune Responses.

Authors:  Vanesa Stojanovska; Monica Prakash; Rachel McQuade; Sarah Fraser; Vasso Apostolopoulos; Samy Sakkal; Kulmira Nurgali
Journal:  Biomed Res Int       Date:  2019-02-18       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.